Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS628 plus methotrexate versus Actemra/Yameluo plus methotrexate in moderate to severe rheumatoid arthritis
ChiCTR2000033930Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of HS628 in rheumatoid arthritis (RA), sponsored by Peking Union Medical College Hospital. Primary endpoint: Proportion achieving ACR20 at Week 24. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
HS628
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2000033930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033930.